Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in Glioblastoma

Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in Glioblastoma

Glioblastoma (GBM) is a deadly and incurable brain cancer with limited therapeutic options. PFI-3 is a small-molecule bromodomain (BRD) inhibitor of the BRM/BRG1 subunits of the SWI/SNF chromatin remodeling complex. The objective of this study is to determine the efficacy of PFI-3 as a potential GBM...

Full description

Bibliographic Details
Main Authors: Chuanhe Yang, Yinan Wang, Michelle M. Sims, Yali He, Duane D. Miller, Lawrence M. Pfeffer
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pharmaceuticals
Subjects:
glioblastoma
BRG1
BRM
SWI/SNF
gene expression
temozolomide
Online Access:https://www.mdpi.com/1424-8247/14/9/904

Internet

https://www.mdpi.com/1424-8247/14/9/904

Similar Items